Most patients experienced fevers and neurotoxicity such as lethargy or confusion for two or three days after the cells are injected, but the side effects were manageable, Bagley said. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/gileads-car-t-therapy-successfully-shrinks-tumors-in-recurrent-glioblastoma-patients/121558661